UroGen Pharma (URGN) Cash & Current Investments (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Cash & Current Investments data on file, last reported at $140.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 28.39% year-over-year to $140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.3 million (down 28.39% YoY) and the FY2025 annual result came in at $120.5 million, down 49.11% from the prior year.
• Cash & Current Investments improved to $140.3 million in Q1 2026, from $120.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $249.6 million in Q3 2024 to a low of $47.3 million in Q2 2023.
• A 5-year average of $143.4 million and a median of $137.0 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 52.32% — and 2024, when it soared 409.67%.
• Tracing URGN's Cash & Current Investments over 5 years: stood at $100.0 million in 2022, then surged by 37.02% to $137.0 million in 2023, then jumped by 72.8% to $236.7 million in 2024, then sank by 49.11% to $120.5 million in 2025, then advanced by 16.45% to $140.3 million in 2026.
• The last three Cash & Current Investments figures came in at $140.3 million (Q1 2026), $120.5 million (Q4 2025), and $127.0 million (Q3 2025), per Business Quant data.